What is tirzepatide? Questions answered from the trial record

What is tirzepatide, and is it a peptide like Ozempic?

Tirzepatide is a synthetic peptide, a chain of 39 amino acids, with a C20 fatty diacid attached at position 20 (Coskun et al., Molecular Metabolism, 2018). The US Mounjaro label says it is based on the GIP sequence and activates the GIP and GLP-1 receptors (DailyMed, 2 September 2026). Ozempic's active ingredient, semaglutide, is a GLP-1 analogue with 94% sequence homology to human GLP-1 (US Ozempic label, DailyMed, 10 June 2026), produced using recombinant DNA technology in yeast and chemical modification (TGA assessment report for Ozempic, October 2020). So Ozempic and Mounjaro both contain peptides, but they are different molecules.

'Peptide' is a chemical class: a short chain of amino acids. What the two labels share is a fatty di-acid that enables albumin binding, albumin being the carrier protein in blood. The Mounjaro label says this prolongs the half-life, and the Ozempic label says albumin binding is the main protraction mechanism of semaglutide (DailyMed, 2 September 2026 and 10 June 2026). They differ in the receptors they activate, a difference set out side by side in tirzepatide vs semaglutide.

Where tirzepatide comes from traces the molecule from its 2018 discovery paper to its registered form.

Is tirzepatide the same as Mounjaro, and what is it called in Australia?

Tirzepatide is the generic name, and Mounjaro is its brand name in Australia (TGA assessment report for Mounjaro, 20 September 2024). The TGA register entry records Mounjaro as registered on 23 December 2022 for type 2 diabetes. The weight-management entry records a decision date of 9 September 2024 and a registration date of 10 September 2024, and a further entry dated 2 June 2025 adds obstructive sleep apnoea (read 14 October 2026). The TGA Medicines Safety Update of 3 June 2025 lists Mounjaro as the dual GIP/GLP-1 agonist marketed in Australia at that date. In the United States, the same molecule has two brand names: Mounjaro, and Zepbound, whose label lists weight reduction and obstructive sleep apnoea (US labels, DailyMed, 2 September 2026).

'Types' of tirzepatide are really types of product. The Product Information published with the 2024 assessment report lists vials and pre-filled pens (including a KwikPen presentation). Compounded copies are a separate category: the TGA's update of 18 June 2024 records that amendments to the Therapeutic Goods Regulations 1990 stop pharmacists compounding, and supplying to patients, medicines containing GLP-1 receptor agonist analogues compounded on or after 1 October 2024, and notes that compounded products are not identical to TGA-approved products.

Is Mounjaro 'stronger' than the tirzepatide compound? They share a molecule, so the word fits neither. What differs is that the registered product has a TGA register entry and Product Information. Research-use tirzepatide, listed in the catalogue as tirzepatide reference material with unverified current certification, is a laboratory compound. It is not a medicine, is not a substitute for one, and is not for human or animal use.

What does the label record happening in the body with tirzepatide, and what did trials record early on?

The Mounjaro label reports lower fasting and after-meal glucose, decreased food intake, reduced glucagon and delayed gastric emptying in human pharmacodynamic summaries for type 2 diabetes; the summary gives no participant count and does not predict an individual response (US Mounjaro label, DailyMed, 2 September 2026). Gastric emptying is the speed at which the stomach empties. The TGA Product Information reports peak blood levels 8 to 72 hours after study exposure in human pharmacokinetic data, with no participant count in that passage and no individual prediction (Mounjaro Product Information, August 2024). In SURMOUNT-1, a maker-funded trial of 2,539 adults with obesity or overweight and no diabetes, the most common adverse events were gastrointestinal and mostly mild to moderate, a trial-group finding rather than an individual prediction (Jastreboff et al., NEJM, 2022).

Both receptors tirzepatide activates are present in many tissues. The Australian Product Information lists the pancreatic alpha and beta cells, brain, heart, blood vessels, immune cells, gut and kidney for both receptors, and fat cells for the GIP receptor (Mounjaro Product Information, version dated August 2024). The Product Information describes where the receptors are, not a measured effect.

In the human gastric-emptying marker study described in the US Mounjaro label, whose summary omits clinical population and participant count, peak paracetamol concentration at the initial study assessment was 50% lower and arrived one hour later; this measures a marker rather than an individual's experience (DailyMed, 2 September 2026). The sources cited here report group results and not what any individual feels.

What is the success rate of tirzepatide? What SURMOUNT-1 found

Tirzepatide has no single success rate, because trials report different endpoints. In SURMOUNT-1, published in the New England Journal of Medicine in 2022, 2,539 adults with obesity or overweight and a weight-related condition, without diabetes were randomised, double-blind, to one of three tirzepatide arms or placebo for 72 weeks, and mean weight change was −15.0%, −19.5% and −20.9% on tirzepatide against −3.1% on placebo, in an analysis that counted participants regardless of treatment discontinuation, group averages from a maker-funded trial that do not predict any one person's result (Jastreboff et al., NEJM, 2022). In SURMOUNT-1, a 72-week double-blind trial of 2,539 adults with obesity or overweight and a weight-related condition, without diabetes, weight reductions of 5% or more occurred in 85%, 89% and 91% of the tirzepatide arms against 35% on placebo, and reductions of 20% or more in 50% and 57% of the two higher arms against 3%, trial-group shares that do not predict an individual outcome (Jastreboff et al., NEJM, 2022).

In SURMOUNT-1, a maker-funded trial of 2,539 adults with obesity or overweight and no diabetes, adverse events caused treatment to stop in 4.3%, 7.1% and 6.2% of the tirzepatide arms against 2.6% on placebo, trial-group rates that cannot predict an individual event or establish results for people with type 2 diabetes (Jastreboff et al., NEJM, 2022). The SURPASS programme asks that question instead, and the SURPASS-2 trial, an open-label, maker-funded trial of 1,879 adults with type 2 diabetes, reported estimated mean HbA1c falls of 2.01 to 2.30 percentage points on tirzepatide against 1.86 on semaglutide at 40 weeks (Frías et al., NEJM, 2021).

SURMOUNT-4 tested maintenance. In SURMOUNT-4, 670 adults with obesity or overweight and no diabetes were randomised after completing a 36-week open-label lead-in to continue tirzepatide or receive placebo, and weight changed by −5.5% on continued tirzepatide and +14.0% on placebo from week 36 to week 88, results limited to selected lead-in completers in a withdrawal-design trial, not all adults with obesity (Aronne et al., JAMA, 2024). How the SURPASS and SURMOUNT trials differ explains each endpoint.

Does Mounjaro wear off after five days? What the half-life means

A half-life is the time for the amount in the blood to fall by half, rather than a time to full clearance. In human pharmacokinetic label data, tirzepatide has an elimination half-life of approximately 5 days and mean absolute bioavailability of 80%; the cited summary gives no participant count, and these are group estimates rather than individual measurements (US Mounjaro label, DailyMed, 2 September 2026). After one half-life about half remains, and after two about a quarter; those fractions define the measure.

The molecule is broken down by the body's own machinery: the label describes proteolytic cleavage of the peptide backbone, beta-oxidation of the fatty diacid and amide hydrolysis, with metabolites leaving mainly in urine and faeces. In human pharmacokinetic label data, semaglutide has an elimination half-life of approximately 1 week and an estimated presence in circulation of about 5 weeks after final study exposure; the cited passage supplies no participant count, and these are group estimates rather than individual predictions (US Ozempic label, DailyMed, 10 June 2026).

What is the bad side of tirzepatide? Adverse events recorded in the trials

In the two pooled placebo-controlled weight-reduction trials in the US Zepbound label (2,519 adults with obesity or overweight, with and without type 2 diabetes, on tirzepatide and 958 on placebo), nausea occurred in 25% to 29% of tirzepatide arms against 8% on placebo, diarrhoea in 19% to 23% against 8%, vomiting in 8% to 13% against 2%, and constipation in 11% to 17% against 5%, group figures that do not predict any one person's experience (DailyMed, 2 September 2026). In the Zepbound human trial pool (2,519 tirzepatide and 958 placebo adults with obesity or overweight, with and without type 2 diabetes), 4.8% to 6.7% of tirzepatide arms permanently stopped treatment because of adverse reactions against 3.4% on placebo, and the label says the majority who stopped did so during the first few months because of gastrointestinal adverse reactions, group figures that do not predict an individual experience (US Zepbound label, DailyMed, 2 September 2026).

The table below sets ten of the label's 16 listed reactions beside placebo. In the Zepbound human trial pool (2,519 tirzepatide and 958 placebo adults with obesity or overweight, with and without type 2 diabetes), hair loss was recorded in 4% to 5% against 1%, and fatigue in 5% to 7% against 3%, group rates that do not predict an individual event (US Zepbound label, DailyMed, 2 September 2026). SURMOUNT-1, a maker-funded trial of 2,539 adults with obesity or overweight and no diabetes, reported that the most common adverse events were gastrointestinal, mostly mild to moderate, a trial-group finding that does not predict an individual experience (Jastreboff et al., NEJM, 2022). In SURPASS-2, an open-label trial of 1,879 adults with type 2 diabetes, serious adverse events were 5% to 7% on tirzepatide and 3% on semaglutide (Frías et al., NEJM, 2021).

Trials also report on what follows stopping, covered further below, and on lean mass, which a selected SURMOUNT-1 body-scan substudy of 160 adults with obesity or overweight and no diabetes (124 on tirzepatide, 36 on placebo) put at about a quarter of weight lost for both groups, a group figure that does not describe any one person's body composition (Look et al., Diabetes, Obesity and Metabolism, 2025). The tirzepatide vs semaglutide page covers how that compares.

What organ is tirzepatide or Ozempic hard on? What the labels warn about

The labels name several organs in their warnings, and the text searched on 14 October 2026 did not describe any medicine as 'hard on' an organ. The US Mounjaro label and the US Ozempic label both carry warnings on acute pancreatitis, acute gallbladder disease (the Mounjaro label says it has occurred in clinical trials) and acute kidney injury due to volume depletion (DailyMed, 2 September 2026 and 10 June 2026). The Australian Product Information says gastrointestinal events may lead to dehydration that could worsen kidney function, including acute renal failure (Mounjaro Product Information, TGA, version dated August 2024). The Mounjaro label's boxed warning states that tirzepatide caused thyroid C-cell tumours in rats, with no animal count in the warning and unknown human relevance; that rat finding does not establish a human result (US Mounjaro label, DailyMed, 2 September 2026).

Other label warnings concern the eyes, with temporary worsening of diabetic retinopathy linked to rapid glucose lowering; the stomach, with delayed emptying and severe gastrointestinal reactions; and the lungs, with pulmonary aspiration reported in people undergoing general anaesthesia or deep sedation (Mounjaro Product Information, version dated August 2024). The TGA's update of 3 June 2025 reports a class-wide warning being added to the Product Information and Consumer Medicine Information of these medicines about the risk of aspiration during general anaesthesia or deep sedation (TGA Medicines Safety Update, 3 June 2025).

The Australian Product Information also records that tirzepatide has not been studied in people with a history of pancreatitis. A warning records what the label or Product Information says, and it is not a finding about any one person's risk.

What do the labels list as contraindications for tirzepatide?

The Australian Product Information lists one contraindication: known hypersensitivity to tirzepatide or any ingredient in Mounjaro (Mounjaro Product Information, TGA, version dated August 2024). The US label adds a personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 (US Mounjaro label, DailyMed, 2 September 2026). The TGA assessment report gives Mounjaro pregnancy category D, defined there as drugs which have caused, are suspected to have caused or may be expected to cause an increased incidence of human fetal malformations or irreversible damage (TGA assessment report for Mounjaro, 20 September 2024).

Australia and the United States do not word these sections identically, and both documents are revised over time. The Australian document says safety and efficacy in people under 18 have not been established (Mounjaro Product Information, version dated August 2024), while the US Mounjaro label lists type 2 diabetes in paediatric patients aged 10 years and over (DailyMed, 2 September 2026).

Why are people stopping Wegovy and other GLP-1 medicines, and what happens when treatment stops?

Studies record both how often people stop and what follows, but the PubMed abstracts and ClinicalTrials.gov records searched for this page on 14 October 2026 did not find one reason for stopping. In STEP 1, a double-blind, maker-funded trial of 1,961 adults with overweight or obesity and no diabetes, gastrointestinal events caused 4.5% of semaglutide participants to stop against 0.8% on placebo, a trial-population result that does not predict an individual event (Wilding et al., NEJM, 2021). In an observational US cohort of 18,386 matched adults with overweight or obesity, who received tirzepatide or semaglutide in formulations labelled for type 2 diabetes and which cannot show cause, follow-up ended by discontinuation in 52.5% of semaglutide users and 55.9% of tirzepatide users (Rodriguez et al., JAMA Internal Medicine, 2024).

What follows stopping is better measured. In the exploratory STEP 1 extension of 327 adults with overweight or obesity and no diabetes, those who had received semaglutide regained 11.6 percentage points of the weight they had lost by one year after treatment ended, about two-thirds of the earlier loss, a group result that does not predict any one person's course (Wilding et al., Diabetes, Obesity and Metabolism, 2022). In SURMOUNT-4, 670 adults with obesity or overweight and no diabetes were randomised after completing a 36-week lead-in, and weight rose 14.0% from week 36 to 88 in those randomised to placebo, while 16.6% of them kept at least 80% of their loss against 89.5% of those continuing tirzepatide, results limited to selected lead-in completers in a withdrawal-design trial, not all adults with obesity (Aronne et al., JAMA, 2024).

Those are group results from trials: the maker of semaglutide funded STEP 1, and the abstracts of SURMOUNT-4 and of the STEP 1 extension name no funder. They cannot explain why one person stops, and 'tolerability' is a label, not a finding, unless the paper measured it.

Why do some people say they feel so good on semaglutide or GLP-1 medicines?

The PubMed abstracts and ClinicalTrials.gov records searched for this page on 14 October 2026 did not find a published study that explains why individuals report feeling good. What trials measured is depressive-symptom scores. In a post hoc analysis of the double-blind, placebo-controlled STEP 1, 2, 3 and 5 trials of semaglutide in people without known major psychopathology, which was written about psychiatric safety and cannot say that anyone's mood changed because of the drug, the 3,377 adults with overweight or obesity in STEP 1 to 3 started with average scores indicating no or minimal depressive symptoms, and at week 68 the PHQ-9 score averaged 2.0 on semaglutide and 2.4 on placebo, an estimated treatment difference of −0.56 (95% CI −0.81 to −0.32), which the authors describe as small and not clinically meaningful (Wadden et al., JAMA Internal Medicine, 2024).

Feelings reported to friends or on social media are not data. Reports of feeling well may reflect weight change, blood-sugar change or something else, and the PubMed abstracts and ClinicalTrials.gov records searched for this page on 14 October 2026 did not find a trial that tested which. That question is broader than the psychiatric-safety analysis measured.

Is tirzepatide stronger than Ozempic, and what medicine is stronger than tirzepatide?

'Stronger' is not an end point in the trials cited here. In SURPASS-2, an open-label, maker-funded trial of 1,879 adults with type 2 diabetes, estimated mean HbA1c fell by 2.01 to 2.30 percentage points on tirzepatide against 1.86 on semaglutide (Frías et al., NEJM, 2021). In SURMOUNT-5, an open-label, maker-funded 72-week trial of 751 adults with obesity, the least-squares mean weight change was −20.2% against −13.7% (Aronne et al., NEJM, 2025). The PubMed abstracts and ClinicalTrials.gov records searched for this page on 14 October 2026 did not find a head-to-head trial showing larger average changes on a registered medicine than on tirzepatide. Retatrutide remains a separate trial record, rather than a demonstrated ranking against tirzepatide (Jastreboff et al., NEJM, 2023).

In the double-blind, maker-funded Phase 2 trial of 338 adults with obesity or overweight and a weight-related condition, the least-squares mean weight change in retatrutide's higher arm was −24.2% against −2.1% on placebo at 48 weeks, a trial-group result that cannot predict an individual outcome or establish a cross-trial ranking (Jastreboff et al., NEJM, 2023). In REDEFINE 1, a 68-week double-blind trial of 3,417 adults with obesity or overweight and no diabetes funded by the maker of semaglutide, estimated mean weight change on the cagrilintide–semaglutide combination was −20.4% against −3.0% on placebo, a group result from a different trial population rather than an individual prediction or direct comparison with tirzepatide (Garvey et al., NEJM, 2025). The full comparison and the retatrutide comparison page set them out.

Which other GLP-1 medicines are registered in Australia?

The TGA Medicines Safety Update of 3 June 2025 lists the GLP-1 receptor agonists then marketed in Australia as Ozempic and Wegovy (semaglutide), Trulicity (dulaglutide), and Victoza and Saxenda (liraglutide), with Mounjaro as the dual GIP/GLP-1 agonist. It states that Ozempic, Trulicity and Victoza are approved for adults with type 2 diabetes, and Saxenda and Wegovy for chronic weight management. Later TGA register entries add indications for Ozempic (18 August 2025) and Wegovy (26 February 2024, 19 December 2024 and 30 March 2026), read 14 October 2026. The TGA's assessment report for Mounjaro records that liraglutide was first registered in 2010, dulaglutide in 2015 and semaglutide in 2019 (TGA AusPAR, 20 September 2024).

This page lists neighbours by mechanism and does not rank them. Tirzepatide vs semaglutide sets out what two head-to-head trials found for the nearest comparison.

What have studies found about tirzepatide and insulin resistance?

One Phase 1 mechanism study measured a combined index of insulin secretion and sensitivity in adults with type 2 diabetes. In a randomised, double-blind, small study run at two centres in Germany, 117 adults with type 2 diabetes on metformin were enrolled (45 on tirzepatide, 44 on semaglutide, 28 on placebo), the 28-week analysis covered 39, 39 and 24 of them, and the maker of tirzepatide funded it. In the 28-week mechanistic analysis of 102 adults with type 2 diabetes on metformin, selected from 117 enrolled, tirzepatide increased the clamp disposition index, a measure combining insulin secretion and insulin sensitivity, by an estimated treatment difference of 1.92 over placebo (95% CI 1.59 to 2.24) and 0.84 over semaglutide (95% CI 0.46 to 1.21), and the result does not cover people with insulin resistance but no diabetes (Heise et al., The Lancet Diabetes & Endocrinology, 2022). In that small 28-week mechanistic analysis of 102 adults with type 2 diabetes on metformin from 117 enrolled, the difference from semaglutide reflected higher total insulin secretion rate and insulin sensitivity, laboratory measures rather than long-term clinical outcomes (Heise et al., The Lancet Diabetes & Endocrinology, 2022).

Limits come first. The semaglutide arm had 44 participants in the safety population and 39 in the pharmacodynamic analysis (Heise et al., 2022). The study reports a measured laboratory effect and not a clinical outcome.

What does research show about tirzepatide and dementia?

The PubMed abstracts and ClinicalTrials.gov records searched for this page on 14 October 2026 did not find a randomised trial of tirzepatide for dementia, and the related semaglutide trials address a different molecule. In evoke and evoke+, two double-blind phase 3 trials, 3,808 adults with early Alzheimer's disease were randomised to oral semaglutide or placebo; the mean change in the Clinical Dementia Rating Sum of Boxes at week 104 was 2.3 and 2.2 on semaglutide against 2.3 and 2.1 on placebo, and both trials were discontinued due to negative clinical outcome, in a different molecule from tirzepatide, funded by the maker of semaglutide, in people who already had Alzheimer's disease (Cummings et al., The Lancet, 2026). A 2026 scoping review of tirzepatide in neurological disease, with searches through 30 September 2025, found 22 studies: 11 preclinical, three retrospective cohorts and eight case reports, and the clinical designs among them cannot show cause (Hawas et al., Brain and Behavior, 2026).

Hawas et al.'s 2026 review inventories preclinical experiments, retrospective cohorts and case reports, rather than a randomised tirzepatide dementia trial. Retrospective associations do not establish cause, and case reports lack a control group. A hypothesis is a question for testing, not a measured clinical result.

Is Mounjaro listed on the PBS, and what is Ozempic's status in Australia?

The PBS Medicine Status page for tirzepatide, current as at 1 October 2026, records that the company has advised it is not proceeding in the listing process on the Pharmaceutical Benefits Scheme (PBS) at this time and that the process has ceased. It gives 'Not applicable' against 'Medicine listed on the PBS' and records no PBS listing. The Pharmaceutical Benefits Advisory Committee (PBAC) recommended listing for adults with inadequately controlled type 2 diabetes at its 11 March 2026 meeting (PBS Medicine Status page, 1 October 2026). Ozempic is a registered prescription medicine, first entered on the register on 28 August 2019, and the TGA said in June 2025 that Trulicity and Ozempic are available on the PBS (authority streamlined) (TGA Medicines Safety Update, 3 June 2025).

The PBAC had considered tirzepatide in July 2023 (not recommended), November 2024 (not recommended) and July 2025 (deferred) before the March 2026 recommendation (PBS Medicine Status pages, current as at 1 October 2026). This page reports status and does not discuss prices or where to obtain a product. The Australian law hub covers how the Poisons Standard treats research peptides.